The IFOPA is pleased to share this news from āshibio announcing the dosing of the first participant in its ANDECAL study, a Phase 2/3 clinical trial evaluating the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of andecaliximab in patients with fibrodysplasia ossificans progressiva (FOP).

Read the full press release

Learn more about the ANDECAL trial which is recruiting 12 patients in the United States who are ≥ 12 years of age. The trial is open to individuals with any FOP-causing mutation (variant) in the ACVR1 gene. Participants need to have had evidence of FOP disease activity within one year of the screening visit.